# A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

> **NCT04366713** · PHASE2 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 6 (actual)

## Conditions studied

- HER2 Amplified Breast Cancer

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Capecitabine
- **DRUG:** Loperamide

## Key facts

- **NCT ID:** NCT04366713
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-30
- **Primary completion:** 2021-12-28
- **Final completion:** 2021-12-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366713, "A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04366713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*